TY - JOUR
T1 - Simplified breast risk tool integrating questionnaire risk factors, mammographic density, and polygenic risk score
T2 - Development and validation
AU - Rosner, Bernard
AU - Tamimi, Rulla M.
AU - Kraft, Peter
AU - Gao, Chi
AU - Mu, Yi
AU - Scott, Christopher
AU - Winham, Stacey J.
AU - Vachon, Celine M.
AU - Colditz, Graham A.
N1 - Funding Information:
B. Rosner reported grants from NIH during the conduct of the study. R.M. Tamimi reported grants from NIH/NCI during the conduct of the study. P. Kraft reported grants from National Institutes of Health during the conduct of the study. Y. Mu reported grants from NIH during the conduct of the study. C.M. Vachon reported grants from NCI during the conduct of the study. G.A. Colditz reported grants from Breast Cancer Research Foundation during the conduct of the study; personal fees from GRAIL Inc outside the submitted work; in addition, G.A. Colditz had a patent for Up To Date author with royalties paid. No other disclosures were reported.
Funding Information:
The authors would like to thank the participants and staff of the Nurses’ Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. This project was funded by a NIH cohort infrastructure grant (UM1 CA186107), and a program project grant (P01 CA87969) from the NCI, and by a grant (BCRF 20-028) to Dr. Colditz from the Breast Cancer Research Foundation. Mayo Mammography Health Study was funded by NCI R01 CA97396, R01 CA177150, and Mayo Clinic Cancer Center (Rochester, MN).
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/4
Y1 - 2021/4
N2 - Background: Clinical use of breast cancer risk prediction requires simplified models. We evaluate a simplified version of the validated Rosner-Colditz model and add percent mammographic density (MD) and polygenic risk score (PRS), to assess performance from ages 45-74. We validate using the Mayo Mammography Health Study (MMHS). Methods: We derived the model in the Nurses' Health Study (NHS) based on: MD, 77 SNP PRS and a questionnaire score (QS; lifestyle and reproductive factors). A total of 2,799 invasive breast cancer cases were diagnosed from 1990-2000. MD (using Cumulus software) and PRS were assessed in a nested case-control study. We assess model performance using this case-control dataset and evaluate 10-year absolute breast cancer risk. The prospective MMHS validation dataset includes 21.8% of women age <50, and 434 incident cases identified over 10 years of follow-up. Results: In the NHS, MD has the highest odds ratio (OR) for 10-year risk prediction: ORper SD = 1.48 [95% confidence interval (CI): 1.31-1.68], followed by PRS, ORper SD = 1.37 (95% CI: 1.21-1.55) and QS, ORper SD = 1.25 (95% CI: 1.11-1.41). In MMHS, the AUC adjusted for age + MD + QS 0.650; for age + MD + QS + PRS 0.687, and the NRI was 6% in cases and 16% in controls. Conclusion: A simplified assessment of QS, MD, and PRS performs consistently to discriminate those at high 10-year breast cancer risk. Impact: This simplified model provides accurate estimation of 10-year risk of invasive breast cancer that can be used in a clinical setting to identify women who may benefit from chemopreventive intervention.
AB - Background: Clinical use of breast cancer risk prediction requires simplified models. We evaluate a simplified version of the validated Rosner-Colditz model and add percent mammographic density (MD) and polygenic risk score (PRS), to assess performance from ages 45-74. We validate using the Mayo Mammography Health Study (MMHS). Methods: We derived the model in the Nurses' Health Study (NHS) based on: MD, 77 SNP PRS and a questionnaire score (QS; lifestyle and reproductive factors). A total of 2,799 invasive breast cancer cases were diagnosed from 1990-2000. MD (using Cumulus software) and PRS were assessed in a nested case-control study. We assess model performance using this case-control dataset and evaluate 10-year absolute breast cancer risk. The prospective MMHS validation dataset includes 21.8% of women age <50, and 434 incident cases identified over 10 years of follow-up. Results: In the NHS, MD has the highest odds ratio (OR) for 10-year risk prediction: ORper SD = 1.48 [95% confidence interval (CI): 1.31-1.68], followed by PRS, ORper SD = 1.37 (95% CI: 1.21-1.55) and QS, ORper SD = 1.25 (95% CI: 1.11-1.41). In MMHS, the AUC adjusted for age + MD + QS 0.650; for age + MD + QS + PRS 0.687, and the NRI was 6% in cases and 16% in controls. Conclusion: A simplified assessment of QS, MD, and PRS performs consistently to discriminate those at high 10-year breast cancer risk. Impact: This simplified model provides accurate estimation of 10-year risk of invasive breast cancer that can be used in a clinical setting to identify women who may benefit from chemopreventive intervention.
UR - http://www.scopus.com/inward/record.url?scp=85103863234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103863234&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-0900
DO - 10.1158/1055-9965.EPI-20-0900
M3 - Article
C2 - 33277321
AN - SCOPUS:85103863234
SN - 1055-9965
VL - 30
SP - 600
EP - 607
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 4
ER -